4.7 Article

High-resolution magnetic resonance imaging reveals nuclei of the human amygdala: manual segmentation to automatic atlas

Journal

NEUROIMAGE
Volume 155, Issue -, Pages 370-382

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.neuroimage.2017.04.046

Keywords

Amygdala; Medial temporal lobe; Atlas; Ex vivo; Autism; Alzheimer's

Funding

  1. PHS [DA023427]
  2. NICHD/NIH [F32HD079169]
  3. Alexander von Humboldt Foundation [R21(MH106796), R21 (AG046657), K01AG28521]
  4. National Cancer Institute [1K25CA181632-01]
  5. Genentech Foundation
  6. European Union's Horizon Marie Sklodowska-Curie (project THALAMODEL) [654911]
  7. ERC (project BUNGEE-TOOLS) [677697]
  8. Spanish Ministry of Economy and Competitiveness (MINECO) [TEC2014-51882-P]
  9. NVIDIA hardware award
  10. National Institute for Biomedical Imaging and Bioengineering [P41EB015896, R01EB006758, R21EB018907, R01EB019956, R01-EB013565]
  11. National Institute on Aging [5R01AG008122, R01AG016495]
  12. National Institute of Diabetes and Digestive and Kidney Diseases [1-R21-DK-108277-01]
  13. National Institute for Neurological Disorders and Stroke [R01NS0525851, R21NS072652, R01NS070963, R01NS083534, 5U01NS086625]
  14. Massachusetts ADRC [P50AG005134]
  15. Shared Instrumentation Grants [1S10RR023401, 1S10RR019307, 1S10RR023043]
  16. NIH Blueprint for Neuroscience Research [5U01-MH093765]
  17. multi-institutional Human Connectome Project
  18. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  19. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  20. National Institute on Aging
  21. National Institute of Biomedical Imaging and Bioengineering
  22. Alzheimer's Association
  23. Alzheimer's Drug Discovery Foundation
  24. BioClinica, Inc.
  25. Biogen Idec Inc.
  26. Bristol-Myers Squibb Company
  27. Eisai Inc.
  28. Elan Pharmaceuticals, Inc.
  29. Eli Lilly and Company
  30. F. Hoffmann-La Roche Ltd
  31. Genentech, Inc.
  32. GE Healthcare
  33. Innogenetics, N.V.
  34. IXICO Ltd.
  35. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  36. Johnson & Johnson Pharmaceutical Research & Development LLC.
  37. Medpace, Inc.
  38. Merck Co., Inc.
  39. Meso Scale Diagnostics, LLC.
  40. NeuroRx Research
  41. Novartis Pharmaceuticals Corporation
  42. Pfizer Inc.
  43. Piramal Imaging
  44. Servier
  45. Synarc Inc.
  46. Takeda Pharmaceutical Company
  47. Canadian Institutes of Health Research
  48. Marie Curie Actions (MSCA) [654911] Funding Source: Marie Curie Actions (MSCA)

Ask authors/readers for more resources

The amygdala is composed of multiple nuclei with unique functions and connections in the limbic system and to the rest of the brain. However, standard in vivo neuroimaging tools to automatically delineate the amygdala into its multiple nuclei are still rare. By scanning postmortem specimens at high resolution (100-150 mu m) at 7 T field strength (n = 10), we were able to visualize and label nine amygdala nuclei (anterior amygdaloid, cortico-amygdaloid transition area; basal, lateral, accessory basal, central, cortical medial, paralaminar nuclei). We created an atlas from these labels using a recently developed atlas building algorithm based on Bayesian inference. This atlas, which will be released as part of FreeSurfer, can be used to automatically segment nine amygdala nuclei from a standard resolution structural MR image. We applied this atlas to two publicly available datasets (ADNI and ABIDE) with standard resolution T1 data, used individual volumetric data of the amygdala nuclei as the measure and found that our atlas i) discriminates between Alzheimer's disease participants and age-matched control participants with 84% accuracy (AUC=0.915), and ii) discriminates between individuals with autism and age-, sex- and IQ-matched neurotypically developed control participants with 59.5% accuracy (AUC=0.59). For both datasets, the new ex vivo atlas significantly outperformed (all p < .05) estimations of the whole amygdala derived from the segmentation in FreeSurfer 5.1 (ADNI: 75%, ABIDE: 54% accuracy), as well as classification based on whole amygdala volume (using the sum of all amygdala nuclei volumes; ADNI: 81%, ABIDE: 55% accuracy). This new atlas and the segmentation tools that utilize it will provide neuroimaging researchers with the ability to explore the function and connectivity of the human amygdala nuclei with unprecedented detail in healthy adults as well as those with neurodevelopmental and neurodegenerative disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available